戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                                    ARRY-063 was administered orally to ovalbumin (OVA) sensitized and cha
2                 Capecitabine (825, 1,000, or 1,250 mg/m(2)) was administered orally twice daily on days 1 to 14 every 3 w
3                                Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day
4 was administered once a day on days 1 to 28 and abexinostat was administered orally twice a day on days 1 to 5, 8 to 12,
5                                                   Alisertib was administered orally at 50 mg twice daily for 7 days in 21
6                                                   Alisertib was administered orally in 21-day cycles at the recommended p
7 d potent and selective P2X3 and P2X2/3 receptor antagonist, was administered orally to rats and found to produce highly s
8                                                 Arimoclomol was administered orally, in drinking water, from symptom onse
9                                                     AZD1775 was administered orally twice per day over 2.5 days per week
10                Then, to assess its efficacy in vivo, BTKB66 was administered orally to mice for 7 days before subjecting
11             In both study groups, 5.0 mg/kg of cyclosporine was administered orally twice daily starting 3 days before HS
12                                        Palbociclib 125 mg/d was administered orally on a 21-days-on, 7-days-off schedule.
13                                   Dexamethasone 40 mg daily was administered orally on days 1, 8, 15, and 22 of each cycl
14                                                  Everolimus was administered orally at 10 mg daily and letrozole was admi
15                         In nonclinical studies, fidaxomicin was administered orally at approximately 1 g/kg/d to dogs for
16                               Peanut or placebo (oat) flour was administered orally and participants and the study team w
17 SR largely increased in diabetic subjects only when glucose was administered orally (37.8 +/- 14.9 vs 68.3 +/- 22.8 nmol;
18                                                   Ibrutinib was administered orally at a dose of 560 and 420 mg once dail
19                                                  Ivosidenib was administered orally (100 mg twice daily to 1,200 mg once
20                                                  Ivosidenib was administered orally daily in 28-day cycles.
21                          During dose escalation, ivosidenib was administered orally at 200-1200 mg daily in 28-day cycles
22                                                   Lapatinib was administered orally twice daily at escalating doses start
23                                               Larotrectinib was administered orally (capsule or liquid formulation), on a
24                                                      LCL161 was administered orally, once weekly, on a 21-day cycle to ad
25                                                Lenalidomide was administered orally at a dose of 25 mg on days 1 to 21 of
26 olimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily.
27                                                  Lorlatinib was administered orally to patients at doses ranging from 10
28                         Ibrutinib at a daily dose of 420 mg was administered orally until disease progression or the deve
29                                            Pazopanib 800 mg was administered orally once daily.
30                              Sunitinib (25, 37.5, or 50 mg) was administered orally once daily on three dosing schedules:
31                    Darapladib 160 mg or placebo monotherapy was administered orally once daily for 3 months, and patients
32 in a continuous fashion via subcutaneous implant, whereas P was administered orally in a cyclic fashion.
33         In the dose-escalation phase (n = 47), panobinostat was administered orally thrice weekly every week in combinati
34                          AQX-1125 (450 mg daily) or placebo was administered orally for 7 days.
35                       In groups PROB and LIP/PROB, the PROB was administered orally by addition to the drinking water of
36                                                      PT2385 was administered orally at twice-per-day doses of 100 to 1,80
37                                                 Quizartinib was administered orally at escalating doses of 12 to 450 mg/d
38                         During dose escalation, rogaratinib was administered orally twice daily at 50-800 mg in continuou
39                                                  Sertraline was administered orally or via nasogastric tube at a dose of
40                                                        SM16 was administered orally in formulated chow.
41                                                   Sorafenib was administered orally at 400 mg twice daily on a continuous
42                                                Temozolomide was administered orally within 60 minutes of the end of the 1
43  part, we evaluated escalations in the dose of PLX3397 that was administered orally in patients with solid tumors (dose-e
44                                                   Treatment was administered orally 5 d/wk for 3 months.
45                                  (13)C-glycerol tripalmitin was administered orally as an independent measure of CM TAG m
46                                                  Venetoclax was administered orally for 14 days each cycle.
47                                                  Vorinostat was administered orally daily starting at 180 mg/m(2)/d with
48                          A-988315 (20 or 60 mg/kg) or water was administered orally 90 min before retention testing, foll
49                              Pioglitazone (30 mg/kg weight) was administered orally 1.5 h before and 2 h after the initia
50              Dexamethasone (20 mg [10 mg if age >75 years]) was administered orally on the same days as bortezomib and th